OCTAPHARMA
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1983-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.octapharma.com/
Observational Study of the Use of octaplasLG®.
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 263
- Registration Number
- NCT03369314
- Locations
- 🇫🇷
Infirmerie Protestante de Lyon, Caluire-et-Cuire, France
🇫🇷Clinique Pasteur, Toulouse, France
🇫🇷Hôpital de La Cavale Blanche, Brest, France
The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency
- Conditions
- Interventions
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 102
- Registration Number
- NCT03369301
- Locations
- 🇫🇷
CH William Morey Chalon-sur-Saône, Chalon-sur-Saône, France
🇫🇷CHD Vendée, La Roche-sur-Yon, France
🇫🇷CH Orléans, Orléans, France
Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 14
- Registration Number
- NCT03344003
- Locations
- 🇨🇦
Stollery children's hospital, University of Alberta, Edmonton, Alberta, Canada
🇨🇦Hamilton Health Science center, Toronto, Ontario, Canada
🇨🇦Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Use of Prothrombin Complex Concentrate in Patients Admitted in Emergency Care Units for Severe Bleeding While Receiving Oral Anticoagulants
- Conditions
- Interventions
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 397
- Registration Number
- NCT03320603
- Locations
- 🇫🇷
Groupe Hospitalier de la Haute-Saône Site de Vesoul, Vesoul, France
🇫🇷Centre Hospitalier de Pau, Pau, France
🇫🇷Centre Hospitalier Universitaire de Strasbourg Hôpital de Hautepierre Service de Réanimation, Strasbourg, France
Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ
- Conditions
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 80
- Registration Number
- NCT02962765
- Locations
- 🇫🇷
CHU Hôtel Dieu, Nantes, France
🇫🇷Hopital Pontchaillou, Rennes, France
🇦🇷Centro de Tratamiento de la Hemofilia Cordoba, Córdoba, Argentina
Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 57
- Registration Number
- NCT02954575
- Locations
- 🇧🇬
Specialized Hospital for Active Treatment "Joan Pavel", Sofia, Bulgaria
🇭🇺National Haemophilia Centre, Budapest, Hungary
🇵🇱Korczowski Bartosz Gabinet Lekarski, Rzeszow, Poland
Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.
- Conditions
- Interventions
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 208
- Registration Number
- NCT02740335
- Locations
- 🇺🇦
Octapharma Research Site, Zhytomyr, Ukraine
🇧🇬Octapharma Study Site, Sofia, Bulgaria
🇬🇪Octapharma Research Location - Tbilisi, Tbilisi, Georgia
Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2021-12-23
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 95
- Registration Number
- NCT02728752
- Locations
- 🇷🇺
Orenburg State Medical University Based On Regional Clinical Hospital, Orenburg, Russian Federation
🇺🇸Arthritis & Osteoporosis Clinic, Waco, Texas, United States
🇭🇺Semmelweis University Dermatology Clinic, Budapest, Hungary
Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 142
- Registration Number
- NCT02638207
- Locations
- 🇧🇬
St. Naum Hospital, Sofia, Bulgaria
🇷🇺Neurology Research Centre, Moscow, Russian Federation
🇭🇺Jahn Ferenc Del Pesti Korhaz, Budapest, Hungary
A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push
- Conditions
- Interventions
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 30
- Registration Number
- NCT02503293
- Locations
- 🇦🇺
CampbelltownHospital, Campbelltown, Australia
🇦🇺Canberra Hospital, Canberra, Australia
🇩🇪University Medical Centre Freiburg, Freiburg, Germany